{
  "id": "6440420857b1c7a315000050",
  "type": "factoid",
  "question": "What is Apretude used for?",
  "ideal_answer": "Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36255686"
  ],
  "snippets": [
    {
      "text": "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir extended-release (ER) injectable suspension (Apretude\u2122) is the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis (PrEP). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabotegravir ER injectable suspension is indicated in the USA for PrEP to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing \u2265\u200935 kg who have a negative HIV-1 test prior to initiation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With its convenient, less-frequent dosing schedule and its long-acting formulation enabling intramuscular administration, cabotegravir ER injectable suspension represents a novel and efficacious alternative to daily oral PrEP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36255686",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "HIV-1 pre-exposure prophylaxis"
}